


DOCKET NO.: UNGR-1598



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

22/03  
MAY 4/12/03  
PATENT RECEIVED  
TECH CENTER 1600/2000  
APR 15 2003  
APR 10 2003

**In re Application of:**

Evan C. Unger et al.

Serial No.: 09/699,679

Filing Date: October 30, 2000

Confirmation No.: 8248

Group Art Unit: 1617

Examiner: Shahnam J. Sharareh

**For: NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND  
THERAPEUTIC USE**

EXPRESS MAIL LABEL NO: EV 160093529 US  
DATE OF DEPOSIT: April 10, 2003

Assistant Commissioner for Patents  
Washington DC 20231

Sir:

**AMENDMENT**

This amendment is being submitted in response to the Office Action dated March 12, 2003 issued in connection with the above-identified application. Applicants respectfully request entry of the following amendment, without prejudice.

**IN THE SEQUENCE LISTING:**

Please insert pages 1 to 7 of the Substitute Sequence Listing submitted herewith.

**REMARKS**

Applicants request entry of pages 1 to 7 of the substitute sequence listing submitted herewith. The sequence listing has been amended to explain the genetic source of the sequences. As the sequence listing is supported by the application as filed, no new matter is